相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
Bin Fan et al.
INVESTIGATIONAL NEW DRUGS (2020)
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Juan Eduardo Megias-Vericat et al.
BLOOD REVIEWS (2020)
Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans
Zeen Tong et al.
XENOBIOTICA (2019)
Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report
Eris Tollkuci
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents
Sung-Han Hsiao et al.
CANCER LETTERS (2019)
Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects
David Dai et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy
Heena P. Patel et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite
Jianke Li et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Acute Myeloid Leukemia, Version 3.2019
Martin S. Tallman et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics
Jianke Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia
Caitlin R. Rausch et al.
BLOOD (2019)
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
A. E. Perl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
Eytan M. Stein et al.
BLOOD (2019)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Richard F. Schlenk et al.
BLOOD (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
In vitro inhibition of human nucleoside transporters and uptake of azacitidine by an isocitrate dehydrogenase-2 inhibitor enasidenib and its metabolite AGI-16903
Zeen Tong et al.
XENOBIOTICA (2019)
Venetoclax for AML: changing the treatment paradigm
Daniel A. Pollyea et al.
BLOOD ADVANCES (2019)
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
Juan Eduardo Megias-Vericat et al.
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY (2019)
Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin
Manoj S. Chiney et al.
XENOBIOTICA (2018)
In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions
Anne M. Filppula et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML
Jorge E. Cortes et al.
BLOOD (2018)
Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers
M. Naveed Shaik et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics
Kevin J. Freise et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors
Suresh K. Agarwal et al.
ADVANCES IN THERAPY (2018)
Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies
Kha Le et al.
BLOOD (2018)
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
Sibylle C. Mellinghoff et al.
ANNALS OF HEMATOLOGY (2018)
Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers
Ahmed Hamed Salem et al.
CLINICAL DRUG INVESTIGATION (2017)
Defining Invasive Fungal Infection Risk in Hematological Malignancies: A New Tool for Clinical Practice
Benedetta Rambaldi et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
Jun Li et al.
ONCOTARGET (2017)
Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers
Nagdeep Giri et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug
Handan He et al.
DRUG METABOLISM AND DISPOSITION (2017)
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations
Livio Pagano et al.
BLOOD REVIEWS (2017)
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma
Suresh K. Agarwal et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments
Suresh K. Agarwal et al.
CLINICAL THERAPEUTICS (2017)
Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor
Ahmed Hamed Salem et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study
Suresh K. Agarwal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management
James E. Tisdale
CANADIAN PHARMACISTS JOURNAL (2016)
Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial
Richard F. Schlenk et al.
BLOOD (2016)
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
Elisabet Cuyas et al.
ONCOTARGET (2015)
How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach
Marcio Nucci et al.
BLOOD (2014)
Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
M. Naveed Shaik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers
Catherine Dutreix et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
Jasjeet Bhullar et al.
PLOS ONE (2013)
Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients
Livio Pagano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
分享论文
